Research output per year
Research output per year
Personal profile
Headline
ASSOCIATE PROFESSOR Medicine, Hematology and Medical Oncology
Biography
Fingerprint
Dive into the research topics where Max Sung is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 6 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma
El-Khoueiry, A. B., Kim, R. D., Harris, W. P., Sung, M. W., Waldschmidt, D., Cabrera, R., Garosi, V. L., Ploeger, B. A., Zebger-Gong, H., Brennan, B. J., Wang, Y. A., Mueller, U., Weispfenning, A., Seidel, H., Coppieters, S., Ishida, T. C. & Galle, P. R., 2025, In: Hepatology.Research output: Contribution to journal › Article › peer-review
Open Access -
Hepatocellular carcinoma: Epidemiology, diagnosis and treatment
Mauro, E., de Castro, T., Zeitlhoefler, M., Sung, M. W., Villanueva, A., Mazzaferro, V. & Llovet, J. M., Dec 2025, In: JHEP Reports. 7, 12, 101571.Research output: Contribution to journal › Review article › peer-review
Open Access -
Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study
Piscaglia, F., Ikeda, K., Cheng, A. L., Kudo, M., Ikeda, M., Breder, V., Ryoo, B. Y., Mody, K., Ren, M., Ramji, Z. & Sung, M. W., 15 Apr 2024, In: Cancer. 130, 8, p. 1281-1291 11 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Radioembolization plus Immune Checkpoint Inhibitor Therapy Compared with Radioembolization plus Tyrosine Kinase Inhibitor Therapy for the Treatment of Hepatocellular Carcinoma
Garcia-Reyes, K., Gottlieb, R. A., Menon, K. M., Bishay, V., Patel, R., Patel, R., Nowakowski, S., Sung, M. W., Marron, T. U., Gansa, W. H., Zhang, J., Raja, S. C., Shilo, D., Fischman, A., Lookstein, R. & Kim, E., May 2024, In: Journal of Vascular and Interventional Radiology. 35, 5, p. 722-730.e1Research output: Contribution to journal › Article › peer-review
-
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors
Dasari, A., Hamilton, E. P., Falchook, G. S., Wang, J. S., Li, D., Sung, M. W., Chien, C., Nanda, S., Tucci, C., Hahka-Kemppinen, M. & Paulson, A. S., Jun 2023, In: Investigational New Drugs. 41, 3, p. 421-430 10 p.Research output: Contribution to journal › Article › peer-review
Open Access
Press/Media
-
Incidence and Risk Factors of Chemotherapy-Induced Nausea and Vomiting Among Adult Cancer Patients at Mbarara Regional Referral Hospital: A Prospective Study
20/05/26
1 item of Media coverage
Press/Media
-
Low-Dose Versus Standard-Dose Bevacizumab Plus Sintilimab for Unresectable Hepatocellular Carcinoma: A Real-World Comparative Study of Efficacy and Safety
11/04/26
1 item of Media coverage
Press/Media
-
Pyrotinib Plus Trastuzumab as an Effective Later-Line Therapeutic Strategy for HER2-Positive Metastatic Colorectal Cancer: Results from a Phase II Study
20/11/25
1 item of Media coverage
Press/Media